Anderson, J.J., Wells, G., Verhoeven, A.C. and Felson, D.T. ( 2000) Factors predicting response to treatment in rheumatoid arthritis: The importance of disease duration. Arthritis Rheum43: 22-29.
2.
Bakker, M.F., Jacobs, J.W., Verstappen, S.M. and Bijlsma, J.W. ( 2007) Tight control in the treatment of rheumatoid arthritis: Efficacy and feasibility. Ann Rheum Dis66(Suppl 3): iii56-iii60.
3.
Balsa, A., Del, A.J., Blanco, F., Caliz, R., Silva, L., Sanmarti, R. et al. (2010) Prediction of functional impairment and remission in rheumatoid arthritis patients by biochemical variables and genetic polymorphisms . Rheumatology (Oxford) 49: 458-466.
4.
Boers, M. ( 2009) Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: Case closed?Ann Intern Med151: 668-669.
5.
Boers, M., Verhoeven, A.C., Markusse, H.M., van de Laar, M.A., Westhovens, R., van Denderen, J.C. et al. (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet350: 309-318.
6.
Bos, W.H., Dijkmans, B.A.C., Boers, M., van de Stadt, R.J. and van Schaardenburg, D. ( 2010) Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: A randomised trial. Ann Rheum Dis69: 571-574.
7.
Braun, J., Kastner, P., Flaxenberg, P., Wahrisch, J., Hanke, P., Demary, W. et al. (2008) Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum58: 73-81.
8.
Braun, J. and Rau, R.(2009) An update on methotrexate. Curr Opin Rheumatol21: 216-223.
9.
Breedveld, F.C., Weisman, M.H., Kavanaugh, A.F., Cohen, S.B., Pavelka, K., van Vollenhoven, R. et al. (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum54: 26-37.
10.
Brown, A.K., Conaghan, P.G., Karim, Z., Quinn, M.A., Ikeda, K., Peterfy, C.G. et al. (2008) An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum58: 2958-2967.
11.
Bykerk, V.P. and Hazes, J.M. ( 2010) When does rheumatoid arthritis start and can it be stopped before it does?Ann Rheum Dis69: 473-475.
12.
Calguneri, M., Pay, S., Caliskaner, Z., Apras, S., Kiraz, S., Ertenli, I. et al. (1999) Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol17: 699-704.
13.
Cohen, S. and Fleischmann, R.(2010) Kinase inhibitors: A new approach to rheumatoid arthritis treatment . Curr Opin Rheumatol22: 330-335.
14.
Combe, B. ( 2009) Progression in early rheumatoid arthritis. Best Pract Res Clin Rheumatol23: 59-69.
15.
Combe, B., Landewe, R., Lukas, C., Bolosiu, H.D., Breedveld, F., Dougados, M. et al. (2007) EULAR recommendations for the management of early arthritis: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis66: 34-45.
16.
D’Aura, S.C., Paniagua, R.T., Lindstrom, T.M. and Robinson, W.H. ( 2009) Tyrosine kinases as targets for the treatment of rheumatoid arthritis. Nat Rev Rheumatol5: 317-324.
17.
Emery, P., Breedveld, F.C., Hall, S., Durez, P., Chang, D.J., Robertson, D. et al. (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial. Lancet372: 375-382.
18.
Emery, P., van Vollenhoven, R., Ostergaard, M., Choy, E., Combe, B., Graninger, W. et al. (2009) Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: Similarities and differences across Europe. Ann Rheum Dis68: 456-459.
19.
Feely, M.G. and O’Dell, J.R. ( 2010) Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis. Curr Opin Rheumatol22: 316-320.
20.
Goekoop-Ruiterman, Y.P., de Vries-Bouwstra, J.K., Allaart, C.F., van Zeben, D., Kerstens, P.J., Hazes, J.M. et al. (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum52: 3381-3390.
21.
Gorman, J.D., Lum, R.F., Chen, J.J., Suarez-Almazor, M.E., Thomson, G. and Criswell, L.A. ( 2004) Impact of shared epitope genotype and ethnicity on erosive disease: A meta-analysis of 3,240 rheumatoid arthritis patients. Arthritis Rheum50: 400-412.
22.
Gorter, S.L., Bijlsma, J.W., Cutolo, M., Gomez-Reino, J., Kouloumas, M., Smolen, J.S. et al. (2010) Current evidence for the management of rheumatoid arthritis with glucocorticoids: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis69: 1010-1014.
23.
Hetland, M.L., Stengaard-Pedersen, K., Junker, P., Lottenburger, T., Hansen, I., Andersen, L.S. et al. (2008) Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: Second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis67: 815-822.
24.
Hueber, A.J. and McInnes, I.B.(2009) Is spleen tyrosine kinase inhibition an effective therapy for patients with RA? Nat Clin Pract Rheumatol5: 130-131.
25.
Ikeda, K., Cox, S. and Emery, P. ( 2007) Aspects of early arthritis Biological therapy in early arthritis- overtreatment or the way to go?. Arthritis Res Ther9: 211.
26.
Lipsky, P.E., van der Heijde, D.M., St Clair, E.W., Furst, D.E., Breedveld, F.C., Kalden, J.R. et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med343: 1594-1602.
27.
Machold, K.P., Landewe, R., Smolen, J.S., Stamm, T.A., van der Heijde, D.M., Verpoort, K.N. et al. (2010) The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis69: 495-502.
28.
Mattey, D.L., Brownfield, A. and Dawes, P.T.(2009) Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. J Rheumatol36: 1180-1187.
29.
Molenaar, E.T., Voskuyl, A.E., Dinant, H.J., Bezemer, P.D., Boers, M. and Dijkmans, B.A. ( 2004) Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum50: 36-42.
30.
Morel, J. and Combe, B. ( 2005) How to predict prognosis in early rheumatoid arthritis . Best Pract Res Clin Rheumatol19: 137-146.
31.
Moreland, L.W., O’Dell, J.R., Paulus, H., Curtis, J.R., Bridges Jr, S.L., Zhang, X. et al. (2009) TEAR - Treatment of Early Aggressive RA: A randomized, double-blind, 2-year trial comparing immediate triple DMARD versus MTX plus etanercept to step-up from initial MTX monotherapy. (abstract). Arthritis Rheum60: S707.
32.
Mottonen, T., Hannonen, P., Korpela, M., Nissila, M., Kautiainen, H., Ilonen, J. et al. (2002) Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum46: 894-898.
33.
Pawlik, A., Herczynska, M., Kurzawski, M., Safranow, K., Dziedziejko, V. and Drozdzik, M.(2009) The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide. Pharmacogenomics10: 303-309.
34.
Pincus, T., Marcum, S.B. and Callahan, L.F. ( 1992) Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol19: 1885-1894.
35.
Pincus, T., Yazici, Y. and van Vollenhoven, R. ( 2006) Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials. J Rheumatol33: 2372-2375.
36.
Rantalaiho, V., Korpela, M., Hannonen, P., Kautiainen, H., Jarvenpaa, S., Leirisalo-Repo, M. et al. (2009) The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: The eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum60: 1222-1231.
37.
Saag, K.G., Koehnke, R., Caldwell, J.R., Brasington, R., Burmeister, L.F., Zimmerman, B. et al. (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events. Am J Med96: 115-123.
38.
Scherer, H.U., Dorner, T. and Burmester, G.R. ( 2010) Patient-tailored therapy in rheumatoid arthritis: An editorial review. Curr Opin Rheumatol22: 237-245.
39.
Smolen, J.S., Aletaha, D., Koeller, M., Weisman, M.H. and Emery, P. ( 2007) New therapies for treatment of rheumatoid arthritis. Lancet370: 1861-1874.
40.
St Clair, E.W., van der Heijde, D.M., Smolen, J.S., Maini, R.N., Bathon, J.M., Emery, P. et al. (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum50: 3432-3443.
41.
Stanczyk, J., Ospelt, C. and Gay, S. ( 2008) Is there a future for small molecule drugs in the treatment of rheumatic diseases? Curr Opin Rheumatol20: 257-262.
42.
van der Kooij, S.M., de Vries-Bouwstra, J.K., Goekoop-Ruiterman, Y.P., van Zeben, D., Kerstens, P.J., Gerards, A.H. et al. (2007) Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis66: 1356-1362.
43.
van der Kooij, S.M., le Cessie, S., Goekoop-Ruiterman, Y.P., de Vries-Bouwstra, J.K., van Zeben, D., Kerstens, P.J. et al. (2009) Clinical and radiological efficacy of initial vs. delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis68: 1153-1158.
44.
van Dongen, H., van Aken, J., Lard, L.R., Visser, K., Ronday, H.K., Hulsmans, H.M. et al. (2007) Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial. Arthritis Rheum56: 1424-1432.
45.
van Vollenhoven, R.F., Ernestam, S., Geborek, P., Petersson, I.F., Coster, L., Waltbrand, E. et al. (2009) Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial . Lancet374: 459-466.
46.
Verstappen, S.M., McCoy, M.J., Roberts, C., Dale, N.E., Hassell, A.B. and Symmons, D.P.(2010) Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: Results of the STIVEA trial. Ann Rheum Dis69: 503-509.
47.
Visser, K., Katchamart, W., Loza, E., Martinez-Lopez, J.A., Salliot, C., Trudeau, J. et al. (2009) Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: Integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis68: 1086-1093.
48.
Weinblatt, M.E., Kavanaugh, A., Burgos-Vargas, R., Dikranian, A.H., Medrano-Ramirez, G., Morales-Torres, J.L. et al. (2008) Treatment of rheumatoid arthritis with a Syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum58: 3309-3318.
49.
Weinblatt, M.E., Keystone, E.C., Furst, D.E., Moreland, L.W., Weisman, M.H., Birbara, C.A. et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum48: 35-45.
50.
Weyand, C.M., Klimiuk, P.A. and Goronzy, J.J. ( 1998) Heterogeneity of rheumatoid arthritis: From phenotypes to genotypes. Springer Semin Immunopathol20: 5-22.
51.
Wolbink, G.J., Aarden, L.A. and Dijkmans, B.A.(2009) Dealing with immunogenicity of biologicals: Assessment and clinical relevance. Curr Opin Rheumatol21: 211-215.
